About the Company
We do not have any company description for Lucid Diagnostics Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
4
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Lucid Diagnostics Inc.
Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Lucid Diagnostics Inc (LUCD) reports a 40% revenue increase and strengthens its position with strategic partnerships and a ...
What To Expect From Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings
Lucid Diagnostics Inc (NASDAQ:LUCD) is set to release its Q2 2025 earnings on Aug 13, 2025. The consensus estimate for Q2 ...
Lucid Diagnostics Reports Q2 2025 Financial Results
Pavmed ( ($PAVM) ) has released its Q2 earnings. Here is a breakdown of the information Pavmed presented to its investors. Lucid Diagnostics Inc., ...
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.2 per share a year ago. These ...
Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ: LUCD) Q2 2024 Earnings Conference Call August 12, 2024 8:30 AM ET Company Participants Dr. Lishan Aklog - Chairman, Chief Executive Officer Dennis McGrath - Chief ...
Lucid Diagnostics Announces Closing of Public Offering of ... - Nasdaq
--Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., today announced the closing of its previously announced underwritten ...
Lucid Diagnostics Inc. Annual Cash Flow Statement - MarketWatch
Lucid Diagnostics Inc. Annual cash flow by MarketWatch. View LUCD net cash flow, operating cash flow, operating expenses and cash dividends.
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue ... - Nasdaq
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.
Lucid Diagnostics: Strong Buy Rating on Rising Test Volume and ...
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid ...
Lucid Diagnostics and Collaborators Present New EsoGuardĀ® and EsoCheck ...
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal reflux ...
Lucid Diagnostics Announces Closing of Public Offering of ... - Morningstar
Lucid Diagnostics Announces Closing of Public Offering of Common Stock Provided by PR Newswire Apr 11, 2025, 6:23:00 AM Lucid Diagnostics Announces Closing of Public Offering of Common Stock ...
Similar Companies
Loading the latest forecasts...